Diabetics use glucose monitors. Should non-diabetics use them too?
Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...
Abbott bumps up profit forecast on strong medical device sales
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Click2Houston6d
‘We love this fairly low-risk intervention’: Over-the-counter device is helping people gain insight into their health
Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
GlobalData on MSN6h
Abbott reports sales of $10.6bn for Q3 2024
Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...
Glucose monitors for diabetes have finally been funded – but there's a problem
There are problems within the health system that mean full patient access to training on how to use the insulin pumps will ...
Abbott1d
Strong Performance by Abbott’s Base Business Drives Q3 Earnings
Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...
The Asian Age2d
AI-Powered Insulin Navigator: A Breakthrough in Diabetes Management
By personalizing insulin dosing based on individual patient data, the system outperforms traditional insulin pumps in terms ...
Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits
To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...
Is Abbott Laboratories Stock a Buy?
If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items. Abbott maintains its full-year 2024 organic sales growth guidance range ...